FDA Approves First Medication for Obstructive Sleep Apnea
6 days ago · Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination ...
FDA approves Zepbound® (tirzepatide) as the first and only …
6 days ago · Zepbound ® (tirzepatide) injection is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. It is also approved in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in ...
FDA approves first medication for obstructive sleep apnea — …
1 day ago · The Dec. 20 announcement by the FDA revealed that Eli Lilly’s Zepbound (tirzepatide) was approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
2 days ago · The US Food and Drug Administration (FDA) has approved the obesity treatment tirzepatide (Zepbound, Eli Lilly) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Zepbound Approved for Obstructive Sleep Apnea in Patients …
3 days ago · The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.. Zepbound is a dual ...
Tirzepatide reduced sleep apnea severity by up to nearly two …
Apr 17, 2024 · Tirzepatide meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and without PAP therapy, and based on these results Lilly plans to submit these data for global regulatory reviews.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and …
Jun 21, 2024 · Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide...
Tirzepatide reduced sleep apnea severity by up to nearly two …
Apr 17, 2024 · Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials
Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea
Jun 25, 2024 · Reducing body weight with tirzepatide (Zepbound; Eli Lilly) decreases how often sleep is disrupted for patients who have moderate-to-severe obstructive sleep apnea (OSA) and obesity, results from the SURMOUNT-OSA study show.
First Drug to Treat Obstructive Sleep Apnea Approved by FDA
4 days ago · The Food and Drug Administration (FDA) has approved Zepbound (tirzepatide; Eli Lilly and Company, Indianapolis, IN) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.